ImmuneWalk Therapeutics Overview
ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. The company's Monocyte Targeting Technology (MTT) is designed to selectively block the migration of monocytes from the blood stream into inflamed tissues. With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, The company is advancing its solution (IW-601) to a Ph1 clinical trial.
Cumulative Funding Raised Over Time ($)
$7.0MMay 2025
Latest News
growth-positive
ImmuneWalk Therapeutics Announces Positive Topline Phase 1 SAD Data for Immunology and Inflammation Drug Candidate IW-601
ImmuneWalk Therapeutics, a clinical-stage biotechnology company, announced positive topline data from the single ascending dose (SAD) portion of their Phase 1 POINTGUARD study at the EULAR 2025 conference. The study evaluates IW-601, a monoclonal antibody targeting myeloid cells, demonstrating safety, tolerability, and favorable pharmacokinetics. The trial met all primary and secondary endpoints, showing IW-601s potential to modulate immune and inflammatory diseases by preventing myeloid cells from entering inflamed tissues. The company plans to continue with the multiple ascending dose (MAD) part of the study, with results expected later in 2025. IW-601s novel mechanism offers a differentiated approach compared to existing treatments, with potential applications in diseases like multiple sclerosis and rheumatoid arthritis.
Product Stage
growth-positive
ImmuneWalk Therapeutics Announces $7 Million Seed Financing and Upcoming Presentations of Positive Clinical Results at Upcoming Medical and Industry Conferences
ImmuneWalk Therapeutics, a clinical-stage biotechnology company, has completed a $7 million seed financing round with contributions from an institutional investor and its management team. The company focuses on developing therapies for immune-inflammatory diseases and is currently conducting a Phase 1 clinical trial for its lead candidate, IW-601. This monoclonal antibody targets MOSPD2, an adhesion checkpoint protein, to reduce immune-driven inflammation. The company plans to present positive data from its first-in-human trial at the EULAR 2025 Annual Meeting and BIO International Convention. The funding will help accelerate the development of IW-601 towards additional key milestones in 2025.
InvestmentProduct Stage
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $7M |
| Last funding | $7M |
| Stage | Seed |
| Rounds | 1 |
| Investors | 0 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | immunewalk.com/ |
Locations
Petah Tikva, Israel
Photos & Videos
No files yet
ImmuneWalk Therapeutics Business
Business models
B2C
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatientsCore Technology
—Tags (2)
immuno-theraphybiopharmaceuticalImmuneWalk Therapeutics Financials
$7M
Total funding
Undisclosed
Capital raised
$7M
Last funding
Seed
Funding stage
1
Total rounds
0
Investors
Cumulative Funding Raised Over Time ($)
$7.0MMay 2025
Private Equity Funding
Seed
May 2025
$7M
ImmuneWalk Therapeutics Lifecycle
Cumulative Funding Raised Over Time
$7.0MMay 2025
All Events
Seed
May 2025
$7M
ImmuneWalk Therapeutics News
2 articles
growth-positive
ImmuneWalk Therapeutics Announces Positive Topline Phase 1 SAD Data for Immunology and Inflammation Drug Candidate IW-601
ImmuneWalk Therapeutics, a clinical-stage biotechnology company, announced positive topline data from the single ascending dose (SAD) portion of their Phase 1 POINTGUARD study at the EULAR 2025 conference. The study evaluates IW-601, a monoclonal antibody targeting myeloid cells, demonstrating safety, tolerability, and favorable pharmacokinetics. The trial met all primary and secondary endpoints, showing IW-601s potential to modulate immune and inflammatory diseases by preventing myeloid cells from entering inflamed tissues. The company plans to continue with the multiple ascending dose (MAD) part of the study, with results expected later in 2025. IW-601s novel mechanism offers a differentiated approach compared to existing treatments, with potential applications in diseases like multiple sclerosis and rheumatoid arthritis.
Product Stage
growth-positive
ImmuneWalk Therapeutics Announces $7 Million Seed Financing and Upcoming Presentations of Positive Clinical Results at Upcoming Medical and Industry Conferences
ImmuneWalk Therapeutics, a clinical-stage biotechnology company, has completed a $7 million seed financing round with contributions from an institutional investor and its management team. The company focuses on developing therapies for immune-inflammatory diseases and is currently conducting a Phase 1 clinical trial for its lead candidate, IW-601. This monoclonal antibody targets MOSPD2, an adhesion checkpoint protein, to reduce immune-driven inflammation. The company plans to present positive data from its first-in-human trial at the EULAR 2025 Annual Meeting and BIO International Convention. The funding will help accelerate the development of IW-601 towards additional key milestones in 2025.
InvestmentProduct Stage
ImmuneWalk Therapeutics Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 7 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 7 classification IDs that could be used for matching.
ImmuneWalk Therapeutics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 72/100 |
| Missing | sector, tags, video or image, markets, not claimed |
| BI Verification | Matan Eblagon |
| Registrar ID | 516880986 |
| Creator | Matan Eblagon |
| Creator email | matane@sncentral.org |
| Last update | 2025-06-18T00:00:00.000Z |
| Created | 2025-06-18T00:00:00.000Z |